Vasoactive Intestinal Peptide Can Modulate Immune and Endocrine Responses during Lipopolysaccharide-Induced Acute Inflammation

Bik, Wojciech; Woliñska-Witort, Ewa; Chmielowska, Magdalena; Baranowska-Bik, Agnieszka; Rusiecka-Kuczalek, Elzbieta; Baranowska, B

doi:10.1159/000080145

Cited by 22 publications

(15 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, VIP upregulates production of the anti-inflammatory cytokine, IL-10 (Delgado et al, 1999). In diverse experimental models of inflammation, VIP has shown to improve symptoms and survival (Delgado et al, 1999;Abad et al, 2003;Bik et al, 2004;Juarranz et al, 2005;Martinez et al, 2005;Newman et al, 2005;Gonzalez-Rey and Delgado, 2006). We have recently demonstrated the increased expression of inflammatory gene transcripts and protein in urinary bladder of VIP -/-mice treated with CYP as demonstrated with a superarray and confirmed with enzyme-lined immunoassays (Girard et al, 2008).…”

Section: Discussionmentioning

confidence: 64%

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

et al. 2008

View full text Add to dashboard Cite

Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide widely distributed in neural pathways that regulate micturition. VIP is also an endogenous anti-inflammatory agent that has been suggested for the development of therapies for inflammatory disorders. In the present study, we examined urinary bladder function, hindpaw and pelvic sensitivity in VIP -/-and littermate wildtype controls. We demonstrated increased bladder mass and fewer but larger urine spots on filter paper in VIP -/-mice. Using cystometry in conscious, unrestrained mice, VIP -/-mice exhibited increased void volumes and shorter intercontraction intervals with continuous intravesical infusion of saline. No differences in transepithelial resistance or water permeability were demonstrated between VIP -/-and WT mice; however, an increase in urea permeability was demonstrated in VIP -/-mice. With the induction of bladder inflammation by acute administration of cyclophosphamide (CYP), an exaggerated or prolonged bladder hyperreflexia, hindpaw and pelvic sensitivity were demonstrated in VIP -/-mice. The changes in bladder hyperreflexia and somatic sensitivity in VIP -/-mice may reflect increased expression of neurotrophins and/or or proinflammatory cytokines in the urinary bladder. Thus, these changes may further regulate the neural control of micturition.

show abstract

Section: Discussionmentioning

confidence: 64%

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Conversely, VIP upregulates production of the anti-inflammatory cytokine, IL-10 ( Delgado et al, 1999). In diverse experimental models of inflammation, VIP has shown to improve symptoms and survival (Delgado et al, 1999) (Abad et al, 2003;Bik et al, 2004;Newman et al, 2005;Juarranz et al, 2005;Martinez et al, 2005;Gonzalez-Rey and Delgado, 2006). We have recently demonstrated (Vizzard et al, 2007b) that production of pro-inflammatory compounds including IL-1β, IL-6 and monocyte chemoattract protein (MCP-1; CCL2) is increased in urinary bladder of VIP −/− mice treated with CYP compared to WT.…”

Section: Anti-inflammatory Role Of Vip In Bladder Reflex Pathwaysmentioning

confidence: 99%

Expression of Phosphorylated cAMP Response Element Binding Protein (p-CREB) in Bladder Afferent Pathways in VIP−/− Mice with Cyclophosphamide (CYP)-Induced Cystitis

et al. 2008

View full text Add to dashboard Cite

The expression of phosphorylated cAMP response element binding protein (pCREB) in dorsal root ganglia (DRG) with and without CYP-induced cystitis (150 mg/kg, i.p; 48 hr) was determined in VIP −/− and wildtype (WT) mice. p-CREB-immunoreactivity (IR) was determined in bladder (Fastblue) afferent cells. Nerve growth factor (NGF) bladder content was determined by ELISAs. Basal expression of pCREB-IR in DRG of VIP −/− mice was (p ≤ 0.01) greater in L1, L2, L5-S1 DRG compared to WT mice. CYP treatment in WT mice increased (p ≤ 0.05) pCREB-IR in L1, L2, L5-S1 DRG. CYP treatment in VIP −/− mice (p ≤ 0.01) increased (p ≤ 0.01) p-CREB-IR in L6-S1 DRG compared to WT with CYP. In WT mice, bladder afferent cells (20-38%) in DRG expressed pCREB-IR under basal conditions. With CYP, pCREB-IR increased in bladder afferent cells (60-65%; L6-S1 DRG) in WT mice. In VIP −/− mice, bladder afferent cells (12-58%) expressed pCREB-IR under basal conditions and CYP increased pCREB expression (78-84%) in L6-S1 DRG. Urinary bladder NGF expression in VIP −/− mice under basal conditions or after cystitis was significantly greater than WT. Detrusor smooth muscle thickness was significantly increased in VIP −/− mice. Bladder NGF expression may contribute to differences in pCREB expression.

show abstract

“…Noticeably, all the latest studies regarding the immunomodulator role of PRL focused the attention on paracrineautocrine PRL, produced within the immune system [241,250]. Interestingly, a bidirectional relationship between PRL and immune system was observed, with cytokines influencing PRL production at pituitary stage [224,258,259].…”

Section: A Physiology Of Prl In Neonates and Vlbw Infantsmentioning

confidence: 99%

Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects

Filippi¹,

Poggi²,

Pezzati

2007

CPR

View full text Add to dashboard Cite

Preterm newborns weighing less than 1500 g (very low birth weight infants, VLBW) represent a critical population with high prevalence of morbidities, often requiring hemodynamic stabilization. Dopamine is a natural cathecolamine widely used for this purpose because it exerts pleiotropic anti-shock effects on cardiovascular, renal and endocrine systems, acting on adrenergic and dopaminergic receptors. Dopamine is a first choice drug in VLBW infants for inotropic support and optimisation of renal and splanchnic perfusion, mostly indicated for the treatment of hypotension, symptomatic patent ductus arteriosus and renal failure.Dopamine reversibly suppresses pituitary functions in adults but its effects on endocrine balance have been poorly studied in VLBW infants. Recent studies showed a dose-dependant reduction of TSH and T4 plasmatic levels in dopamine-treated VLBW infants and a positive correlation between dopamine infusion and incidence of transient hypothyroxinemia of prematurity.Further studies demonstrated that dopamine infusion also reduces PRL secretion in VLBW infants. TSH, T4 and PRL suppression rapidly reverses after dopamine withdrawal, when a significant hormonal rebound is observed. Therefore, such iatrogenic suppression probably cannot involve long-term injuries and T4 substitutive administration appears unecessary during short course dopamine treatment.Recent observations suggest that dopamine infusion can prevent early diagnosis of congenital hypothyroidism (CH) when screening programs are merely based on TSH plasmatic levels. Considering the severe neurodevelopmental outcome of undiagnosed CH, other screening strategies should be considered in treated neonates, such as simultaneous T4 and TSH testing and hormonal re-evaluation after dopamine discontinuation.A final issue of this review regards a possibile role of dobutamine as an alternative safer inotropic drug. PART 1. DOPAMINE AND DOBUTAMINE ADMINI-STRATION IN PRETERM INFANTS Clinical BackgroundPreterm infants weighing at birth less than 1500 g are referred to as very low birth weight (VLBW) infants and presently account for about 1-3 % of all neonates [1, 2]. However, they represent a widening subset of neonates with major vulnerability among the whole neonatal population. In fact, VLBW infants show a high incidence of morbitidies and systemic hypotension affects approximately one third of these infants [3]. Therefore, they often require early and careful hemodinamic stabilisation and, as a matter of fact, from 4% to 39% of VLBW infants receive inotropic support [3].Even if at present there are no clear evidences that the treatment of systemic hypotension is beneficial [4,5], such condition is widely and aggressively treated in VLBW infants in order to preserve a proper organ perfusion and an adequate cerebral blood flow [3,4,[6][7][8][9][10][11][12] since hypotension results associated with increased risk of intraventricular haemorrhage and unfavourable neurodevelopmental outcome [13][14][15][16]. Impaired cerebral autoregulation has been dem...

show abstract

Vasoactive Intestinal Peptide Can Modulate Immune and Endocrine Responses during Lipopolysaccharide-Induced Acute Inflammation

Cited by 22 publications

References 44 publications

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

Urinary Bladder Function and Somatic Sensitivity in Vasoactive Intestinal Polypeptide (VIP)−/− Mice

Expression of Phosphorylated cAMP Response Element Binding Protein (p-CREB) in Bladder Afferent Pathways in VIP−/− Mice with Cyclophosphamide (CYP)-Induced Cystitis

Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects

Contact Info

Product

Resources

About